.jpg)
Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (“NewCo”)
Dateline City: KENILWORTH, N.J. NewCo to be a Leading Women’s Health Company; Represents Total Revenue…
Category: Merck Pharmaceutical
FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Dateline City: KENILWORTH, N.J. Filing Receives Priority Review KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as…
Merck Receives Approval for BELSOMRA® (suvorexant) C-IV Label Update to Include Findings from Study of Insomnia in Patients with Mild-to-Moderate Alzheimer’s Disease
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J. — Merck (NYSE: MRK), known as MSD outside the…
Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck Announces Second-Quarter 2020 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
US cancer centre leaders secretly worked for China, internal report finds
Six researchers who resigned last month from Florida’s Moffitt Cancer Center admitted to opening secret…
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
Dateline City: KENILWORTH, N.J. Submission Based on PROfound, the First Phase 3 Trial Evaluating a…
Merck Completes Acquisition of ArQule
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review
Dateline City: KENILWORTH, N.J. Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in…
Prostate cancer: only one in four men with metastatic disease gets recommended chemotherapy
A national audit shows that only one in four men with advanced prostate cancer receives…
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy
Dateline City: KENILWORTH, N.J. KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With…
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Dateline City: KENILWORTH, N.J. Phase 3 KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint…
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
Dateline City: KENILWORTH, N.J. LYNPARZA Reduced the Risk of Disease Progression or Death by 47%…
Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)
Dateline City: KENILWORTH, N.J. Action Represents Another Milestone for the Global Partnership Against Ebola KENILWORTH,…
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H)…
FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare
Dateline City: MADISON, N.J. Strategic Transaction Benefits and Improves Aquaculture Health and Performance MADISON, N.J.–(BUSINESS…
LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemotherapy
Dateline City: KENILWORTH, N.J. Oncologic Drugs Advisory Committee Voted That LYNPARZA Demonstrated a Favorable Benefit-Risk…
Merck Begins Tender Offer to Acquire ArQule
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck Receives Positive EU CHMP Opinion for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Infections Due to Aerobic Gram-Negative Organisms in Adults with Limited Treatment Options
Dateline City: KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada,…
Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
Dateline City: KENILWORTH, N.J. New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at…
Merck to Acquire ArQule, Advancing Leadership in Oncology
Dateline City: KENILWORTH, N.J. & BURLINGTON, Mass. Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion…
LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
Dateline City: KENILWORTH, N.J. AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or…
Merck to Present at the Evercore ISI HealthCONx Conference 2019
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dateline City: KENILWORTH, N.J. Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be…
Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Dateline City: KENILWORTH, N.J. Third Approval for KEYTRUDA in First-Line NSCLC in China in Less…
European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the…
Merck Announces First-Quarter 2020 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…